{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:04:46Z","timestamp":1790370286730,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymgme.2026.110258","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:34:03Z","timestamp":1789400043000},"page":"110258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute and chronic neurological manifestations of acute porphyria"],"prefix":"10.1016","volume":"149","author":[{"given":"E.","family":"Pischik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2026.110258_bb0005","article-title":"Long-term follow-up of acute porphyria in female patients: update of clinical outcome and life expectancy","volume":"30","author":"Baumann","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110258_bb0010","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.amjmed.2014.06.036","article-title":"Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium","volume":"127","author":"Bonkovsky","year":"2014","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ymgme.2026.110258_bb0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/oxfordjournals.qjmed.a067184","article-title":"The neuropathy of acute intermittent porphyria","volume":"38","author":"Ridley","year":"1969","journal-title":"QJM"},{"key":"10.1016\/j.ymgme.2026.110258_bb0020","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1007\/s00415-004-0584-z","article-title":"Clinical features predictive of a poor prognosis in acute porphyria [letter]","volume":"251","author":"Pischik","year":"2004","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110258_bb0025","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s00415-023-11586-5","article-title":"Pathogenesis of acute encephalopathy in acute hepatic porphyria","volume":"270","author":"Pischik","year":"2023","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110258_bb0030","first-page":"104","article-title":"Quantifying the impact of symptomatic acute hepatic porphyria on well-being via patient-reported outcomes: results from the Porphyria worldwide patient experience research (POWER) study","volume":"64","author":"Dickey","year":"2022","journal-title":"JIMD Rep."},{"issue":"9","key":"10.1016\/j.ymgme.2026.110258_bb0035","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1111\/liv.15966","article-title":"Long-term complications in acute porphyria","volume":"44","author":"Pischik","year":"2024","journal-title":"Liver Int."},{"issue":"24","key":"10.1016\/j.ymgme.2026.110258_bb0040","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2026.110258_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/01.md.0000152454.56435.f3","article-title":"An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity","volume":"84","author":"Hift","year":"2005","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.ymgme.2026.110258_bb0050","doi-asserted-by":"crossref","first-page":"573","DOI":"10.4103\/ijem.IJEM_677_17","article-title":"Acute intermittent porphyria presented with acute intestinal pseudo-obstruction","volume":"22","author":"Pahadiya","year":"2018","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110258_bb0055","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-2796.2000.00653.x","article-title":"Could attacks of abdominal pain in cases of acute intermittent porphyria be due to intestinal angina?","volume":"247","author":"Lithner","year":"2000","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110258_bb0060","first-page":"72","article-title":"Neurological manifestations of acute intermittent porphyria","volume":"55","author":"Pischik","year":"2009","journal-title":"Cell Mol. Biol. (Noisy-le-grand)"},{"key":"10.1016\/j.ymgme.2026.110258_bb0065","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/jnnp.48.10.1025","article-title":"Autonomic neuropathy in acute intermittent porphyria","volume":"48","author":"Laiwah","year":"1985","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymgme.2026.110258_bb0070","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/path.1700710222","article-title":"The neuropathology of acute porphyria","volume":"71","author":"Gibson","year":"1956","journal-title":"J. Pathol. Bacteriol."},{"key":"10.1016\/j.ymgme.2026.110258_bb0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-0773.1991.tb00409.x","article-title":"A comparative study of the effects of delta-aminolaevulinic acid and the GABAA agonist, muscimol, in rat jejunal preparations","volume":"69","author":"Cutler","year":"1991","journal-title":"Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.ymgme.2026.110258_bb0080","doi-asserted-by":"crossref","DOI":"10.4292\/wjgpt.v16.i4.110843","article-title":"Enteric nervous system as a therapeutic target in gastrointestinal disorders","volume":"16","author":"Agrawal","year":"2025","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2026.110258_bb0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2007-1007139","article-title":"Acute porphyrias: pathogenesis of neurological manife stations","volume":"18","author":"Meyer","year":"1998","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ymgme.2026.110258_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1004125","article-title":"Pain in acute hepatic porphyrias: updates on pathophysiology and management","volume":"13","author":"Kazamel","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymgme.2026.110258_bb0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF01243439","article-title":"The effect of porphyrin precursors on monosynaptic reflex activity in the isolated hemisected frog spinal cord","volume":"36","author":"Loots","year":"1975","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ymgme.2026.110258_bb0100","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-2008-1040701","article-title":"Neurologic manifestations of acute porphyria","volume":"2","author":"Bonkowsky","year":"1982","journal-title":"Semin. Liver Dis."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110258_bb0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11910-020-01078-8","article-title":"Porphyric neuropathy: pathophysiology, diagnosis, and updated management","volume":"20","author":"Kazamel","year":"2020","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.ymgme.2026.110258_bb0110","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s00415-008-0779-9","article-title":"Is screening for urinary porphobilinogen useful among patients with acute polyneuropathy or encephalopathy?","volume":"255","author":"Pischik","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2026.110258_bb0115","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1399-0004.2008.01061.x","article-title":"A novel 19-bp deletion of exon 15 in the HMBS gene causing acute intermittent porphyria associating with rhabdomyolysis during an acute attack","volume":"74","author":"Yrjonen","year":"2008","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2026.110258_bb0120","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1212\/WNL.58.7.1118","article-title":"Porphyria presenting with bilateral radial motor neuropathy: evidence of a novel gene mutation","volume":"58","author":"King","year":"2002","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ymgme.2026.110258_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.70068","article-title":"The initial clinical and electrophysiological characteristics of different subtypes of Guillain-Barr\u00e9 syndrome diagnosed based on serial electrophysiological examinations","volume":"14","author":"Yang","year":"2024","journal-title":"Brain Behav."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110258_bb0130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1440-1789.2006.00751.x","article-title":"Acute intermittent porphyria with peripheral neuropathy complicated by small-fiber neuropathy","volume":"27","author":"Hsieh","year":"2007","journal-title":"Neuropathology"},{"key":"10.1016\/j.ymgme.2026.110258_bb0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00690977","article-title":"Peripheral nerve changes in porphyric neuropathy: findings in sural nerve biopsy","volume":"42","author":"Anzil","year":"1978","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110258_bb0140","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ymgme.2019.10.011","article-title":"Porphyria-induced posterior reversible encephalopathy syndrome and central nervous system dysfunction","volume":"28","author":"Jaramillo-Calle","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110258_bb0145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM197101072840104","article-title":"Blood volume and bilirubin production in acute intermittent porphyria","volume":"284","author":"Bloomer","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2026.110258_bb0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1042\/cs0720103","article-title":"Delta-aminolaevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects","volume":"72","author":"Gorchein","year":"1987","journal-title":"Clin. Sci."},{"key":"10.1016\/j.ymgme.2026.110258_bb0155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF00235687","article-title":"Delta-aminolaevulinic acid and amino acid neurotransmitters","volume":"38","author":"Brennan","year":"1981","journal-title":"Mol. Cell. Biochem."},{"issue":"10","key":"10.1016\/j.ymgme.2026.110258_bb0160","doi-asserted-by":"crossref","first-page":"6792","DOI":"10.1007\/s12035-019-1553-y","article-title":"Arginine vasopressin and posterior reversible encephalopathy syndrome pathophysiology: the missing link?","volume":"56","author":"Largeau","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ymgme.2026.110258_bb0165","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1001\/archinte.1993.00410170078008","article-title":"Early administration of heme arginate for acute porphyric attacks","volume":"153","author":"Mustajoki","year":"1993","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ymgme.2026.110258_bb0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/TACG.S48605","article-title":"An update of clinical management of acute intermittent porphyria","volume":"8","author":"Pischik","year":"2015","journal-title":"Appl. Clin. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110258_bb0175","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ymgme.2016.08.006","article-title":"Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: a qualitative study","volume":"119","author":"Naik","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110258_bb0180","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40271-018-0319-3","article-title":"Patient perspective on acute intermittent porphyria with frequent attacks: a disease with intermittent and chronic manifestations","volume":"11","author":"Simon","year":"2018","journal-title":"Patient"},{"issue":"5","key":"10.1016\/j.ymgme.2026.110258_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15595","article-title":"Myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS): a preliminary survey among patients in Switzerland","volume":"9","author":"Tschopp","year":"2023","journal-title":"Heliyon"},{"issue":"9","key":"10.1016\/j.ymgme.2026.110258_bb0190","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1007\/s12325-022-02172-8","article-title":"Patient perspective on acute hepatic porphyria with sporadic attacks: a chronic disease with substantial health-related quality of life impacts","volume":"39","author":"Wheeden","year":"2022","journal-title":"Adv. Ther."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110258_bb0195","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1176\/ajp.142.12.1430","article-title":"High prevalence of intermittent acute porphyria in a psychiatric patient population","volume":"142","author":"Tishler","year":"1985","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.ymgme.2026.110258_bb0200","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/hep.30936","article-title":"EXPLORE: a prospective, multinational, natural history study of patients with acute hepatic porphyria with recurrent attacks","volume":"71","author":"Gouya","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ymgme.2026.110258_bb0205","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/070674371506000402","article-title":"Chronic pain, psychopathology, and DSM-5 somatic symptom disorder","volume":"60","author":"Katz","year":"2015","journal-title":"Can. J. Psychiatr."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110258_bb0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13023-023-02653-1","article-title":"Brazilian registry of patients with porphyria: REBRAPPO study","volume":"18","author":"Souza","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"issue":"10","key":"10.1016\/j.ymgme.2026.110258_bb0215","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/jama.1965.03090230005001","article-title":"Oral contraceptive agents and the management of acute intermittent porphyria","volume":"194","author":"Perlroth","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2026.110258_bb0220","first-page":"99","article-title":"An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom","volume":"36","author":"Schulenburg-Brand","year":"2017","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2026.110258_bb0225","first-page":"57","article-title":"Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms","volume":"22","author":"Marsden","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2026.110258_bb0230","article-title":"Benefits of prophylactic heme therapy in severe acute intermittent porphyria","volume":"19","author":"Yarra","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.110258_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.712305","article-title":"Prophylactic Heme Arginate infusion for acute intermittent Porphyria","volume":"12","author":"Kuo","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110258_bb0240","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000327","article-title":"Long-term management and treatment of acute intermittent porphyria with recurring attacks using pharmacological prophylaxis","volume":"7","author":"Kuo","year":"2023","journal-title":"Hepatol. Commun."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110258_bb0245","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10545-018-0178-z","article-title":"Medical and financial burden of acute intermittent porphyria","volume":"41","author":"Neeleman","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110258_bb0250","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1016\/S2352-3026(26)00044-X","article-title":"Guidelines for the management of acute porphyria: recommendations from the International Porphyria Network","volume":"13","author":"Edel","year":"2026","journal-title":"Lancet Haematol."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110258_bb0255","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ymgme.2022.01.002","article-title":"Givosiran in acute intermittent porphyria: a personalized medicine approach","volume":"135","author":"Poli","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110258_bb0260","first-page":"146","article-title":"Recurrent symptoms of acute intermittent porphyria after biochemical normalization with givosiran-an ongoing clinical conundrum","volume":"64","author":"Ma","year":"2022","journal-title":"JIMD Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2026.110258_bb0265","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/lt.25959","article-title":"European liver and intestine transplant association. Liver transplantation for acute intermittent porphyria","volume":"27","author":"Lissing","year":"2021","journal-title":"Liver Transpl."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110258_bb0270","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/cpt.2597","article-title":"Givosiran likely inhibits cytochrome P450 more substantially than reported","volume":"112","author":"Bins","year":"2022","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922600541X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922600541X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:37:21Z","timestamp":1790368641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671922600541X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":54,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S109671922600541X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110258","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute and chronic neurological manifestations of acute porphyria","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110258"}}